[2]
Knight DM,Trinh H,Le J,Siegel S,Shealy D,McDonough M,Scallon B,Moore MA,Vilcek J,Daddona P, Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Molecular immunology. 1993 Nov [PubMed PMID: 8232330]
[3]
Maini RN,Breedveld FC,Kalden JR,Smolen JS,Davis D,Macfarlane JD,Antoni C,Leeb B,Elliott MJ,Woody JN,Schaible TF,Feldmann M, Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis and rheumatism. 1998 Sep [PubMed PMID: 9751087]
[4]
Steeland S,Libert C,Vandenbroucke RE, A New Venue of TNF Targeting. International journal of molecular sciences. 2018 May 11 [PubMed PMID: 29751683]
[5]
Sfikakis PP, The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Current directions in autoimmunity. 2010 [PubMed PMID: 20173395]
[6]
Tracey D,Klareskog L,Sasso EH,Salfeld JG,Tak PP, Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacology [PubMed PMID: 18155297]
[7]
Schottelius AJ,Moldawer LL,Dinarello CA,Asadullah K,Sterry W,Edwards CK 3rd, Biology of tumor necrosis factor-alpha- implications for psoriasis. Experimental dermatology. 2004 Apr [PubMed PMID: 15086336]
[8]
Wong M,Ziring D,Korin Y,Desai S,Kim S,Lin J,Gjertson D,Braun J,Reed E,Singh RR, TNFalpha blockade in human diseases: mechanisms and future directions. Clinical immunology (Orlando, Fla.). 2008 Feb [PubMed PMID: 17916444]
[9]
Esposito E,Cuzzocrea S, TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma. Current medicinal chemistry. 2009 [PubMed PMID: 19689289]
[10]
Waage A,Halstensen A,Espevik T, Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet (London, England). 1987 Feb 14 [PubMed PMID: 2880163]
[11]
Fiers W, Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS letters. 1991 Jul 22 [PubMed PMID: 1649771]
[12]
Feldmann M, Development of anti-TNF therapy for rheumatoid arthritis. Nature reviews. Immunology. 2002 May [PubMed PMID: 12033742]
[13]
Uyemura K,Yamamura M,Fivenson DF,Modlin RL,Nickoloff BJ, The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. The Journal of investigative dermatology. 1993 Nov [PubMed PMID: 7693825]
[14]
Mitoma H,Horiuchi T,Tsukamoto H,Ueda N, Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists. Cytokine. 2018 Jan [PubMed PMID: 27567553]
[15]
Charles P,Elliott MJ,Davis D,Potter A,Kalden JR,Antoni C,Breedveld FC,Smolen JS,Eberl G,deWoody K,Feldmann M,Maini RN, Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. Journal of immunology (Baltimore, Md. : 1950). 1999 Aug 1 [PubMed PMID: 10415055]
[16]
Danese S,Sans M,Scaldaferri F,Sgambato A,Rutella S,Cittadini A,Piqué JM,Panes J,Katz JA,Gasbarrini A,Fiocchi C, TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. Journal of immunology (Baltimore, Md. : 1950). 2006 Feb 15 [PubMed PMID: 16456024]
[17]
Ritchlin CT,Haas-Smith SA,Li P,Hicks DG,Schwarz EM, Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. The Journal of clinical investigation. 2003 Mar [PubMed PMID: 12639988]
[18]
Souto-Carneiro MM,Mahadevan V,Takada K,Fritsch-Stork R,Nanki T,Brown M,Fleisher TA,Wilson M,Goldbach-Mansky R,Lipsky PE, Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. Arthritis research [PubMed PMID: 19500335]
[19]
Leipe J,Skapenko A,Lipsky PE,Schulze-Koops H, Regulatory T cells in rheumatoid arthritis. Arthritis research [PubMed PMID: 15899057]
[20]
Bayry J,Lacroix-Desmazes S,Dasgupta S,Kazatchkine MD,Kaveri SV, Efficacy of regulatory T-cell immunotherapy: are inflammatory cytokines key determinants? Nature reviews. Immunology. 2008 Jan [PubMed PMID: 18049489]
[21]
Wasserman MJ,Weber DA,Guthrie JA,Bykerk VP,Lee P,Keystone EC, Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. The Journal of rheumatology. 2004 Oct [PubMed PMID: 15468353]
[22]
Rajagopalan M,Mital A, Biologics use in Indian psoriasis patients. Indian dermatology online journal. 2016 Nov-Dec [PubMed PMID: 27990383]
[23]
Hanauer SB,Feagan BG,Lichtenstein GR,Mayer LF,Schreiber S,Colombel JF,Rachmilewitz D,Wolf DC,Olson A,Bao W,Rutgeerts P, Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (London, England). 2002 May 4 [PubMed PMID: 12047962]
[24]
Monaco C,Nanchahal J,Taylor P,Feldmann M, Anti-TNF therapy: past, present and future. International immunology. 2015 Jan [PubMed PMID: 25411043]
[25]
Aygun D,Sahin S,Adrovic A,Barut K,Cokugras H,Camcıoglu Y,Kasapcopur O, The frequency of infections in patients with juvenile idiopathic arthritis on biologic agents: 1-year prospective study. Clinical rheumatology. 2018 Nov 17 [PubMed PMID: 30448935]
[27]
Archer R,Hock E,Hamilton J,Stevens J,Essat M,Poku E,Clowes M,Pandor A,Stevenson M, Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews. Health technology assessment (Winchester, England). 2018 Nov [PubMed PMID: 30501821]
[28]
Svenson M,Geborek P,Saxne T,Bendtzen K, Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford, England). 2007 Dec [PubMed PMID: 18032541]
[30]
Barland C,Kerdel FA, Addition of low-dose methotrexate to infliximab in the treatment of a patient with severe, recalcitrant pustular psoriasis. Archives of dermatology. 2003 Jul [PubMed PMID: 12873907]
[31]
Heller MM,Wu JJ,Murase JE, Fatal case of disseminated BCG infection after vaccination of an infant with in utero exposure to infliximab. Journal of the American Academy of Dermatology. 2011 Oct [PubMed PMID: 21920245]
[32]
Salliot C,Dougados M,Gossec L, Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Annals of the rheumatic diseases. 2009 Jan [PubMed PMID: 18203761]